Over the last 17years, clinical trials conducted worldwide have demonstrated the efficacy of
arsenic trioxide (As2O3) in the treatment of relapsed acute promyelocytic leukemia (APL).
Currently, the role of As2O3 in front-line therapy is under investigation. Recent trials in the
US have demonstrated that the addition of As2O3 to standard treatment regimens improves
survival outcomes in patients with APL and may allow a reduction in cytotoxic chemotherapy
exposure. As2O3 has also shown efficacy in other malignancies, particularly multiple …